Effect of Statins on Serum Apolipoprotein J and Paraoxonase-1 Levels in Patients With Ischemic Heart Disease Undergoing Coronary Angiography
- 2 April 2008
- journal article
- other
- Published by SAGE Publications in Angiology
- Vol. 59 (2) , 137-144
Abstract
It has been proposed that apolipoprotein J (apo J) and paraoxonase-1 (PON1) correlate with the extent and severity of ischemic heart disease (IHD). This article compares apo J and PON1 serum concentrations, PON1 activity, and the apo J/PON1 ratio in 138 IHD patients (64 statins users and 74 statin nonusers) referred for angiography and possible percutaneous coronary intervention. The effect of statin treatment on apo J and PON1 concentrations, PON1 activity, and the degree of coronary artery stenosis were evaluated. In both groups, apo J levels were increased, whereas PON1 concentration and activity decreased. IHD patients on statins had significantly lower apo J concentration and higher PON1 concentration and activity. Patients on statins had less coronary artery stenosis. High apo J levels, low PON1 levels, low PON1 activity, and a high apo J/PON1 ratio were associated with IHD. Statin treatment reverses these changes, probably by multiple beneficial actions.Keywords
This publication has 41 references indexed in Scilit:
- Serum Apolipoprotein J in Health, Coronary Heart Disease and Type 2 Diabetes MellitusJournal of Atherosclerosis and Thrombosis, 2006
- Low Paraoxonase Activity Predicts Coronary Events in the Caerphilly Prospective StudyCirculation, 2003
- Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarctionExperimental Gerontology, 2002
- Paraoxonase and AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Distribution and Synthesis of Apolipoprotein J in the Atherosclerotic AortaArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- DNA Polymorphisms in Two Paraoxonase Genes (PON1 and PON2) Are Associated with the Risk of Coronary Heart DiseaseThe American Journal of Human Genetics, 1998
- Genetic Polymorphism of Paraoxonase and the Risk of Coronary Heart DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetesThe Lancet, 1995
- Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonaseAtherosclerosis, 1993
- The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidationBiochemical Journal, 1993